Abstract

Background and Objectives. Urothelial carcinoma of the bladder is more common than urothelial carcinoma of the upper urinary tract. Carcinoma of the bladder is the tenth most common cancer in the world, with 570,000 new cases and 213,000 deaths annually. Men are significantly more likely than women to develop bladder cancer, with an incidence of 9.5 per 100,000 and a mortality of 3.3 per 100,000, which are rates approximately four times those seen among women globally. Clinicopathological profiling is highly significant in bladder carcinoma because the majority of specimens are received through TURBT. Materials and Methods. This observational descriptive study takes a retrospective approach. The population of this study consists of paraffin blocks obtained from biopsy, transurethral resection of bladder tumor, and cystectomy that were used to diagnose urothelial carcinoma of the bladder through histopathological analysis in the Dr. Soetomo General Academic Hospital between January 2018 and December 2022. The demographic and histopathological data were taken from the patients’ medical records. Results. The majority of patients were men (88%). The average age of the patients was 58.65 years, with a range of 21–80 years and peak incidence occurring at 51–60 years (39%). The procedure most frequently employed was TURBT (68.48%), and squamous differentiation was the most frequent histologic finding (87.5%). The most common type of urothelial carcinoma of the bladder found on urine cytopathology examination was negative for high-grade urothelial carcinoma (81%). Conclusions. The clinicopathological profile is very important in determining the prognostic factor in urothelial carcinoma of the bladder. Most patients herein were men in the age group of 51–60 years. The procedure most frequently employed was TURBT. Most tumors comprised urothelial carcinoma with squamous differentiation, and the majority was negative for high-grade urothelial carcinoma on urine cytopathological examination.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call